All In Biotech

Drug Trial Radar · NCT07154069

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Adaptive Immunotherapy for Locoregional Nasopharyngeal Carcinoma: a Randomized, Controlled, Multicenter, Phase 3 Clinical Trial

Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

802

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Sep 2031

Study completion Sep 2033

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To assess whether radiotherapy alone is non-inferior to concurrent chemoradiotherapy with respect to event-free survival and superior in reducing treatment-related nausea in low-risk locoregionally advanced nasopharyngeal carcinoma patients who achieve complete or partial response and undetectable serum EBV-DNA following induction chemoimmunotherapy. 2. To evaluate whether adjuvant capecitabine and immunotherapy after concurrent chemoradiotherapy improves event-free survival compared to adjuvant immunotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma patients with stable disease or detectable serum EBV-DNA after induction chemoimmunotherapy.

Conditions

  • Nasopharyngeal Cancinoma (NPC)

Interventions

  • Radical radiotherapy of nasopharynx and neckRadiation

    Radical radiotherapy of nasopharynx and neck

  • CapecitabineDrug

    Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year

  • Concurrent chemoradiotherapy (cCRT)Drug

    Concurrent chemoradiotherapy

  • ToripalimabDrug

    Adjuvant Toripalimab (240mg day1, Q3W )

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: 3 year
  2. Incidence rates of vomiting as assessed by CTCAE v5.0Time frame: 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.